Front-line treatment for advanced pulmonary adenocarcinoma based on EGFR mutation status.
S. Wang
No relevant relationships to disclose
H. Yang
No relevant relationships to disclose
W. Ou
No relevant relationships to disclose
Q. Fang
No relevant relationships to disclose